1. Home
  2. MDWD vs III Comparison

MDWD vs III Comparison

Compare MDWD & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.75

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$5.89

Market Cap

251.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
III
Founded
2000
2006
Country
Israel
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
238.5M
251.4M
IPO Year
2014
2007

Fundamental Metrics

Financial Performance
Metric
MDWD
III
Price
$18.75
$5.89
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$37.50
$7.00
AVG Volume (30 Days)
84.8K
323.3K
Earning Date
11-20-2025
11-03-2025
Dividend Yield
N/A
3.04%
EPS Growth
N/A
N/A
EPS
N/A
0.19
Revenue
$20,932,000.00
$241,289,000.00
Revenue This Year
$15.89
N/A
Revenue Next Year
$25.33
$3.63
P/E Ratio
N/A
$31.17
Revenue Growth
6.15
N/A
52 Week Low
$14.14
$2.95
52 Week High
$22.51
$6.45

Technical Indicators

Market Signals
Indicator
MDWD
III
Relative Strength Index (RSI) 55.18 54.83
Support Level $18.55 $5.85
Resistance Level $18.96 $6.05
Average True Range (ATR) 0.57 0.15
MACD 0.01 -0.01
Stochastic Oscillator 57.37 16.67

Price Performance

Historical Comparison
MDWD
III

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About III Information Services Group Inc.

Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.

Share on Social Networks: